Stereotactic Radiotherapy (SBRT/SRS) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stereotactic radiotherapy is a precision radiation oncology technique that delivers very high doses of ionising radiation to a discrete tumour target with sub-millimetre accuracy, while imposing steep dose gradients at the tumour margins to spare adjacent healthy tissues. The word 'stereotactic' refers to the three-dimensional coordinate system used to localise the target relative to a fixed reference frame, enabling precise repositioning of the patient and radiation beam for each treatment fraction.

The term encompasses two closely related but technically distinct approaches:

• Stereotactic Radiosurgery (SRS): Delivery of the entire ablative dose in a single fraction. The term 'radiosurgery' was coined by Swedish neurosurgeon Lars Leksell in 1951 to describe his Gamma Knife system, which treats intracranial lesions using focused beams from 192 radioactive cobalt-60 sources arranged in a hemispherical array. Modern SRS is also delivered by LINAC-based systems and the robotic CyberKnife.
• Stereotactic Body Radiation Therapy (SBRT) — also called Stereotactic Ablative Radiotherapy (SABR): Delivery of ablative doses in a small number of fractions (typically 3–8 fractions), allowing treatment of extracranial tumours where single-fraction delivery is constrained by proximity to critical structures such as the central bronchial tree, oesophagus, or bowel.

The biological rationale for SBRT/SRS differs from conventional fractionated radiotherapy. The very large dose per fraction (>5 Gy, compared with the standard 1.8–2.0 Gy per fraction) exploits high linear-quadratic (LQ) model radiobiological effects and, importantly, induces unique direct vascular endothelial damage and immunogenic cell death pathways not triggered by conventional fractionation. These mechanisms underpin the 'ablative' effect — the ability to achieve local control rates exceeding 90% in early-stage lung cancer and brain metastases, comparable to surgical resection in many disease settings.

Stereotactic radiotherapy has established indications across multiple cancer types and anatomical sites, with the evidence base growing rapidly through phase III randomised trials.

Intracranial indications (SRS):

• Brain metastases: SRS is standard-of-care for 1–4 brain metastases ≤3–4 cm (and increasingly for 5–10 lesions under JLGK0901 and NCCTG N0574 trial guidance), providing equivalent survival to surgical resection with better quality of life and cognitive preservation versus whole-brain radiotherapy (WBRT).
• Vestibular schwannoma (acoustic neuroma): Single-fraction SRS with the Gamma Knife achieves tumour control rates of 95% at 10 years, comparable to microsurgery, with lower cranial nerve morbidity.
• Arteriovenous malformations (AVM): SRS obliterates the AVM nidus in 80–85% of cases at 2–3 years, eliminating haemorrhage risk.
• Trigeminal neuralgia: Gamma Knife SRS targeting the trigeminal nerve root achieves pain relief in 75–80% of patients refractory to medication.
• Meningioma, pituitary adenoma, ependymoma: Established SRS indications with high control rates.

Extracranial indications (SBRT/SABR):

• Early-stage non-small cell lung cancer (NSCLC): SBRT (typically 54 Gy in 3 fractions or 48 Gy in 4 fractions for peripheral tumours) is the standard treatment for stage I NSCLC in medically inoperable patients and an evidence-based alternative to surgery in operable patients (SPACE, STARS, ROSEL trials, pooled analysis by Chang et al.).
• Liver tumours (hepatocellular carcinoma, colorectal liver metastases): SBRT delivers 30–60 Gy in 3–6 fractions; local control rates of 70–90% at 2 years.
• Spine metastases: Spine SBRT ('stereotactic body spine radiotherapy', SBRT) delivers 16–24 Gy in 1–3 fractions; provides durable pain control and tumour control superior to conventional palliative radiotherapy, particularly for radio-resistant histologies (renal cell carcinoma, melanoma, sarcoma).
• Oligometastatic disease: SBRT to 1–5 metastatic sites in oligometastatic NSCLC, colorectal cancer, and breast cancer; SABR-COMET and SINDAS trials demonstrate significant progression-free and overall survival benefits with ablative SBRT versus systemic therapy alone.
• Prostate cancer: Ultra-hypofractionated SBRT (35–36.25 Gy in 5 fractions) for localised prostate cancer is non-inferior to conventional fractionation (PACE-B, HYPO-RT-PC trials).
• Pancreatic cancer, adrenal metastases, lymph node metastases: Emerging indications with active trial programmes.

Patient selection for stereotactic radiotherapy requires multidisciplinary tumour board discussion and careful assessment of tumour characteristics, normal tissue constraints, and patient fitness.

General eligibility criteria:

• Tumour size: SBRT/SRS efficacy diminishes for lesions >5 cm; most protocols limit single-fraction SRS to lesions ≤3 cm (brain) or ≤4 cm (spine). Larger tumours may be better managed with conventional fractionation, surgery, or multi-fraction SBRT.
• Limited number of lesions: SRS for brain metastases is typically offered for ≤10 lesions (with some centres treating more); extracranial SBRT for oligometastatic disease is generally limited to ≤5 sites.
• Tissue diagnosis: Pathological confirmation of malignancy is required before SBRT in most settings, except when biopsy poses unacceptable risk and radiological features are definitively diagnostic.
• Organ function: Liver SBRT requires adequate hepatic reserve (Child-Pugh A or B7); pulmonary SBRT requires assessment of post-treatment lung function (particularly if the patient has pre-existing COPD).
• Proximity to critical structures: Tumours abutting the central bronchial tree, oesophagus, brachial plexus, or bowel require modified protocols (reduced dose per fraction, increased number of fractions) to reduce the risk of late toxicity.

Pre-treatment workup:

• High-resolution MRI (intracranial), contrast-enhanced CT and/or PET-CT (extracranial) for target delineation
• Respiratory motion assessment for thoracic and upper abdominal tumours (4D-CT, respiratory gating, or real-time tumour tracking)
• Simulation CT in the treatment position with immobilisation device (stereotactic frame, thermoplastic mask, body frame, or vacuum bag)
• Radiation physics plan review with dose-volume histogram (DVH) analysis for critical structure constraints
• Multidisciplinary tumour board review and, where appropriate, discussion of equivalent surgical options

Stereotactic radiotherapy is delivered by several technologically distinct platforms, each with specific advantages for particular anatomical sites and tumour types.

Delivery systems:

• Gamma Knife (Elekta): Uses 192 (Perfexion/Icon models) focused cobalt-60 beams converging at a single isocenter. Exclusively intracranial. The Gamma Knife Icon model allows mask-based frameless immobilisation with cone-beam CT image guidance, enabling multi-fraction SRS. Gold-standard for intracranial SRS; 30+ years of clinical outcome data.
• Linear accelerator (LINAC)-based SRS/SBRT: Most modern LINAC platforms (Varian TrueBeam, Elekta Versa HD, Accuray Radixact) can deliver SRS and SBRT using volumetric modulated arc therapy (VMAT), dynamic conformal arcs, or intensity-modulated radiotherapy (IMRT). Flattening filter-free (FFF) beams allow very high dose rates (>1400 MU/min) that shorten treatment time, reduce intra-fraction motion, and optimise biological effect. LINAC-based SRS is suitable for both intracranial and extracranial targets.
• CyberKnife (Accuray): A compact 6 MV LINAC mounted on a robotic arm with 6 degrees of freedom, guided by a stereoscopic X-ray tracking system that corrects for tumour motion in real time (Synchrony respiratory tracking for lung/liver). Unique capability for frameless, non-isocentric treatment with extremely conformal dose distributions. Widely used for spinal SRS, lung SBRT, prostate SBRT, and pancreatic SBRT. The absence of a rigid frame enables hypofractionated treatments for sites with significant respiratory motion.
• MR-Linac (ViewRay MRIdian, Elekta Unity): Integrates a 0.35T or 1.5T MRI scanner with a LINAC, enabling real-time soft-tissue visualisation and online adaptive replanning before each fraction. Particularly valuable for pancreatic, hepatic, and prostate SBRT where day-to-day positional variation is significant.

Representative fractionation schedules:

• Peripheral lung NSCLC: 54 Gy / 3 fx or 48 Gy / 4 fx (BED₁₀ ≥100 Gy)
• Central lung NSCLC: 50 Gy / 5 fx or 60 Gy / 8 fx (to limit central airway dose)
• Brain metastasis SRS: 20–24 Gy / 1 fx (≤2 cm); 18 Gy / 1 fx (2–3 cm); 15 Gy / 1 fx (3–4 cm)
• Spine SBRT: 24 Gy / 2 fx or 24 Gy / 3 fx (de novo); 18–24 Gy / 1 fx (SINS criteria)
• Prostate SBRT: 35–36.25 Gy / 5 fx (PACE-B protocol)
• Liver SBRT: 30–60 Gy / 3–6 fx (institution-specific based on Child-Pugh and liver volume constraints)

Stereotactic radiotherapy has demonstrated compelling efficacy across multiple disease settings, in many cases achieving outcomes comparable to surgery in terms of local control while substantially reducing treatment-related morbidity.

Early-stage lung cancer (NSCLC Stage I–II): SBRT achieves 3-year local control rates of 85–95% and 3-year overall survival of 50–65% in medically inoperable patients — a dramatic improvement over the historical 20–30% survival with conventionally fractionated radiotherapy. A pooled analysis of the STARS and ROSEL randomised trials (Chang et al., Lancet Oncology 2015) comparing SBRT versus surgery in operable stage I NSCLC found non-inferior overall survival at 3 years (95% vs 79%), making SBRT a genuine surgical alternative for patients who prefer non-invasive treatment.

Brain metastases: SRS provides equivalent median survival to surgical resection plus WBRT (Patchell et al.; EORTC 22952-26001) while preserving neurocognitive function by avoiding whole-brain irradiation. The N107C/CEC.3 randomised trial demonstrated superior neurocognitive outcomes with SRS versus surgical bed SRS + WBRT.

Oligometastatic disease (SABR-COMET): The landmark SABR-COMET trial (Palma et al., Lancet 2019) randomised 99 oligometastatic patients with 1–5 metastases to SABR plus standard-of-care versus standard-of-care alone. Median OS was 41 months in the SABR arm versus 28 months in the control arm (HR 0.57; p=0.09). The SABR-COMET-3 and SABR-COMET-10 trials are further defining the benefit.

Quality of life advantages: SBRT is typically completed in 1–5 outpatient visits, causing minimal disruption to daily life. Most patients experience only mild, self-limiting fatigue during treatment. Unlike surgery, there is no anaesthetic risk, no incision, no blood loss, and no prolonged recovery period.

While SBRT/SRS is well-tolerated by most patients, the very high dose per fraction means that even small volumes of normal tissue receiving excessive dose can sustain severe late toxicity. Careful treatment planning and adherence to dose constraints are paramount.

Site-specific toxicities:

• Lung SBRT: Radiation pneumonitis occurs in 10–20% of patients; severe (grade 3+) pneumonitis in 2–5%. Rib fractures adjacent to the chest wall are reported in 5–15% of cases. Central tumour SBRT carries higher risk of bronchial stenosis, bronchopleural fistula, and oesophageal injury (the 'no-fly zone' for high-dose SBRT). Chest wall pain from rib involvement is common and may require analgesics for several months.
• Brain SRS: Radionecrosis (focal radiation injury mimicking tumour progression on MRI) occurs in 5–15% of lesions at 2 years; symptomatic radionecrosis requiring treatment (steroids, bevacizumab, or surgical resection) in 2–5%. With increasing numbers of brain metastases treated simultaneously, the risk of radionecrosis increases proportionally.
• Spine SBRT: Vertebral body fracture occurs in 10–40% of patients (depending on bone density, tumour involvement, and dose), with most being minimally symptomatic and managed conservatively. The most serious risk is radiation myelopathy (spinal cord injury), which is extremely rare (<1%) when doses to the thecal sac are kept within established constraints (e.g., 14 Gy to 0.35 mL of thecal sac in single fraction).
• Liver SBRT: Classic radiation-induced liver disease (RILD) is rare with modern SBRT when mean liver dose constraints (<15–18 Gy for Child-Pugh A) are respected. Biliary stricture and gastric/duodenal ulceration can occur if stomach and duodenum receive high doses.
• Prostate SBRT: Urinary frequency, urgency, and haematuria are common during and shortly after treatment. Late rectal toxicity (grade 3+ rectal bleeding) occurs in 1–3% — similar to conventionally fractionated IMRT.

Secondary malignancy risk: The low-dose bath from VMAT SBRT may theoretically increase the very small risk of radiation-induced secondary cancers, though this is clinically negligible in patients over 50 years and outweighed by the treatment benefit in all established indications.

One of the major advantages of SBRT/SRS is that the treatment itself requires no hospitalisation and minimal recovery time, with patients resuming normal activities the same day or the following day.

During treatment: SBRT is delivered over 1–5 sessions in an outpatient radiation oncology department. Each session typically lasts 30–90 minutes (including setup and imaging), with actual beam-on time of 10–30 minutes. Patients are awake throughout. For lung and liver SBRT, a respiratory motion management device (abdominal compression board, active breathing control, or robotic tracking) is used during treatment. A short course of oral corticosteroids may be prescribed for patients undergoing cranial SRS to prevent transient oedema from acute radiation reaction.

Immediate post-treatment period (0–8 weeks): Most patients experience only mild fatigue for 1–2 weeks. Lung SBRT patients may notice mild chest tightness or a cough at 4–8 weeks (early radiation pneumonitis). Brain SRS patients may experience transient headache or worsening of pre-existing neurological symptoms (pseudo-progression) due to inflammation within 4–8 weeks, which should not be mistaken for treatment failure. Anti-emetics and corticosteroids are prescribed preventively for cranial SRS.

Imaging follow-up and response assessment: CT or MRI is typically performed at 6–8 weeks, 3 months, 6 months, and then every 6 months for 2 years, then annually. Distinguishing radiation-induced changes (fibrosis, scarring in the lung; radionecrosis in the brain) from true tumour progression can be challenging. PET-CT, MR spectroscopy, MR perfusion, and dynamic contrast-enhanced MRI are used as problem-solving tools. The Radiation Therapy Oncology Group (RTOG) and RANO criteria provide standardised frameworks for assessing brain tumour response after SRS.

Long-term care: Patients who achieve durable local control after SBRT for oligometastatic disease may proceed to further SBRT for subsequent oligo-progression at the same or new sites — the concept of 'metastasis-directed therapy' now supported by prospective randomised evidence.

Stereotactic radiotherapy is technology-intensive and commands premium pricing compared to conventional radiotherapy, though it remains substantially less expensive than surgery when recovery costs, anaesthesia, and hospitalisation are factored in.

Estimated costs by region and type:

• United States: SBRT (5 fractions, lung): USD 20,000–45,000; SRS single fraction (brain metastasis): USD 12,000–25,000; prostate SBRT (5 fractions): USD 15,000–30,000. CyberKnife and Gamma Knife procedures carry premium pricing.
• United Kingdom (NHS): Covered for approved indications; private pricing approximately GBP 10,000–25,000 depending on technique and fractions
• India: USD 3,000–8,000 for lung or liver SBRT; USD 3,500–6,000 for brain SRS at leading cancer centres (Tata Memorial, Apollo, Manipal, HCG, RGCIRC)
• Thailand: USD 6,000–14,000 for a full SBRT course at JCI-accredited centres such as Bumrungrad or Bangkok Hospital
• Turkey: USD 4,000–10,000 for SBRT/SRS at major oncology centres in Istanbul
• Singapore: SGD 18,000–40,000 (USD 13,000–30,000) at National Cancer Centre Singapore or Parkway Cancer Centre
• Germany: EUR 10,000–25,000; Germany has among the highest SBRT quality standards in Europe

Key cost drivers:

• Technology platform: Gamma Knife and CyberKnife procedures are priced higher than LINAC-based SBRT due to equipment capital costs and specialised staffing
• Number of fractions: Single-fraction SRS is less expensive per course than 5-fraction SBRT; however, per-fraction cost is higher for SBRT due to longer planning and quality assurance time
• Pre-treatment imaging: Dedicated simulation MRI and 4D-CT add USD 500–2,000 to total costs
• Treatment planning complexity: Tumours near critical structures requiring complex adaptive planning incur higher physics and dosimetry fees

The choice between SBRT and alternative local treatments depends on tumour histology, patient fitness, institutional expertise, and patient preference.

Surgery: Surgical resection (lobectomy, sublobar resection for lung; craniotomy for brain tumours; liver resection for hepatic metastases) remains the preferred option for most operable patients, as it provides definitive pathological staging and traditionally offered superior local control in randomised trials. However, the evidence gap between surgery and SBRT has narrowed considerably. For early-stage lung cancer, the pooled STARS/ROSEL data and subsequent SPACE, CHISEL, and PACIFIC trials have challenged surgical primacy, particularly for patients over 70 years. Shared decision-making between radiation oncology and surgical oncology is strongly recommended.

Conventional fractionated radiotherapy: Standard fractionation (1.8–2.0 Gy per fraction over 5–7 weeks) is used for larger tumours, targets near critical serial structures where SBRT dose constraints cannot be met, and in definitive chemoradiation for unresectable disease (stage III NSCLC, localised oesophageal cancer, head and neck cancers). It is substantially less precise than SBRT and requires many more treatment visits but carries lower per-fraction normal tissue toxicity risk.

Thermal ablation (radiofrequency, microwave, cryoablation): Percutaneous image-guided ablation is a surgical alternative for small hepatic tumours (≤3 cm), lung nodules, and renal cell carcinoma. Multiple meta-analyses show comparable local control to SBRT for small hepatic tumours; the choice is largely institutional and lesion-location dependent.

Proton beam therapy: An alternative particle therapy that delivers no exit dose beyond the target (Bragg peak), potentially reducing integral dose to adjacent normal tissues. Proton SBRT (proton SABR) is an active area of research; currently available at only 40+ centres worldwide, with substantially higher costs than photon SBRT. Proton therapy is preferred for skull base tumours, paediatric CNS tumours, and selected cases where normal tissue constraints cannot be met with photons.

Systemic therapy: For patients with truly widespread metastatic disease (more than 5 sites), systemic therapy (chemotherapy, immunotherapy, targeted therapy) is the appropriate primary treatment. SBRT should be considered complementarily for residual or progressive oligopersistent disease sites after systemic response.